Compare Eli Lilly And Co (LLY) vs Ryanair Holdings plc (RYAAY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Ryanair Holdings plc — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Ryanair Holdings plc trades at $54.24 (market cap $27.11B). The key difference: Eli Lilly And Co is far larger — about 38.4× Ryanair Holdings plc's market cap, and Ryanair Holdings plc pays the higher dividend (1.66%). Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Ryanair Holdings plc for 72 Days on average.
| LLY | RYAAY | |
|---|---|---|
Market Cap | $1.04T | $27.11B |
Volume | 3,064,878 | 2,427,380 |
Sector | Health | Industrials |
52-Week High | $1.28K | $73.82 |
52-Week Low | $799.57 | $51.95 |
Typical Hold Time | 93 Days | 72 Days |
Enterprise Value | $1.09T | $24.18B |
Dividend Yield | 0.59% | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company's weight-loss drug portfolio continues to drive exceptional performance, with Q2 2026 EPS of $8.38 beating expectations by 31%. Technical indicators show bullish moving averages while fundamentals reveal impressive 83.4% gross margins and 102.44% ROE. Recent clinical trial successes for next-generation obesity treatments position Lilly for continued market leadership.
LLY presents a compelling growth story with dominant positioning in the expanding obesity/diabetes market, though elevated valuations (P/E 39.26) and regulatory risks require monitoring. Analyst consensus remains strongly bullish with $1,350 price target representing 15% upside. The primary investment thesis centers on pipeline execution and market expansion opportunities, balanced against competitive pressures and valuation concerns.
RYAAY trades at $54.04, down 3.5% today, with technical indicators showing bearish momentum. The stock shows strong fundamentals with $13.95B revenue, 12.13% net margin, and attractive valuation at P/E 13.43. Recent earnings show mixed results with Q1 beat but Q2 miss. Analyst consensus remains positive with 65% buy ratings despite near-term headwinds from fuel costs and Boeing MAX 10 certification delays.
RYAAY presents a value opportunity with solid profitability and growth prospects, though investors face near-term risks from volatile fuel prices and operational challenges. The airline's low-cost leadership and market share gains support long-term upside, but winter capacity cuts and unhedged oil exposure require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Ryanair Holdings plc
Ryanair is the leading airline group by passenger numbers in Europe. The company employs a low-cost no-frills model to offer low fares to leisure customers on short-haul intra-European routes. In 2020, the most recent pre-pandemic fiscal year, the company carried 149 million passengers, utilizing a fleet of 467 Boeing 737 aircraft across its 1,800 routes. To keep costs low the company serves predominantly lower-cost secondary airports. The company generated sales of EUR 8.5 billion in fiscal 2020.
Read more on RYAAY →
